Patent ID: 7381713
Filing Date: 2008-06-03
Classification: A61K

Abstract:
1. A method of treating a subject having a cancer selected from the group consisting of breast cancer, colon cancer and leukemia, comprising administering to the subject the following combination of agents: (i) 6-methylmercaptopurine riboside (MMPR); (ii) 6-aminonicotinamide (6-AN), wherein MMPR and 6-AN are administered together in an amount sufficient to reduce the adenosine 5′-triphosphate (ATP) level in the cancer cells to 15% of normal or below 15% of normal; and (iii) N-(phosphonacetyl)-L-aspartic acid (PALA); wherein said combination of agents is administered concurrently or sequentially with one or more anti-cancer agents and/or an anti-cancer treatment selected from the group consisting of 5-fluorouracil, phenylalanine mustard, doxorubicin, cisplatin, paclitaxel, radiation, cyclophosphoramide, mitomycin, etoposide, and docetaxel.